# Metabolic Overdrive in Elite Sport: A Systems Model of AMPK–mTOR Oscillation, NAD+ Economy, and Epigenetic Drift

**Authors:** Dan Cristian Mănescu, Camelia Daniela Plăstoi, Răzvan Liviu Petre, Iulius Radulian Mărgărit, Andreea Maria Mănescu, Ancuța Pîrvan

PMC · DOI: 10.3390/ijms27041817 · International Journal of Molecular Sciences · 2026-02-13

## TL;DR

This paper introduces a new model explaining how intense exercise affects metabolism and gene regulation through oscillations between energy-saving and growth states.

## Contribution

The Metabolic Overdrive Model reframes exercise adaptation as a loss of oscillation between AMPK and mTOR signaling.

## Key findings

- Prolonged anabolic signaling after exercise may lead to suppressed AMPK and altered NAD+ economy.
- The model links metabolic stress to epigenetic changes like histone acetylation and DNA methylation.
- It provides testable predictions for molecular signatures of sustained metabolic stress.

## Abstract

Exercise adaptation depends on a dynamic alternation between catabolic and anabolic states coordinated primarily by AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin (mTOR). While transient activation of these pathways underpins beneficial molecular remodeling, the system-level consequences of sustained anabolic drive remain insufficiently conceptualized in exercise biology. This article presents a conceptual mechanistic narrative review integrating evidence from molecular nutrition, exercise physiology, redox biology, and epigenetic regulation to define limits of adaptive signaling. We propose the Metabolic Overdrive Model, a systems-level framework describing the transition from adaptive AMPK–mTOR oscillation to a high-anabolic lock-in state characterized by persistent mTORC1 activation, suppressed AMPK signaling, altered NAD+ economy (SIRT1–PARP imbalance), redox dysregulation, and progressive epigenetic drift. Using exercise and training as models of sustained metabolic stress, we synthesize mechanistic parallels across energy sensing, oxidative signaling, and chromatin regulation without implying pathological causality. The framework generates testable predictions linking prolonged post-exercise anabolic signaling (>24 h) to specific molecular signatures, including AMPK phosphorylation status, NAD+ availability, PARylation, histone acetylation, and DNA methylation dynamics. By reframing exercise adaptation as a loss-of-oscillation phenomenon rather than a linear continuum, this model provides a mechanistic language for hypothesis generation, biomarker-guided periodization, and future experimental validation.

## Linked entities

- **Genes:** PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475], SIRT1 (sirtuin 1) [NCBI Gene 23411], PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142]
- **Chemicals:** NAD+ (PubChem CID 5892)

## Full-text entities

- **Genes:** MAP1LC3A (microtubule associated protein 1 light chain 3 alpha) [NCBI Gene 84557] {aka ATG8E, LC3, LC3A, MAP1ALC3, MAP1BLC3}, EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) [NCBI Gene 1978] {aka 4E-BP1, 4EBP1, BP-1, PHAS-I}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, GGH (gamma-glutamyl hydrolase) [NCBI Gene 8836] {aka GATD10, GH}, RPTOR (regulatory associated protein of MTOR complex 1) [NCBI Gene 57521] {aka KOG1, Mip1}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, FSD1 (fibronectin type III and SPRY domain containing 1) [NCBI Gene 79187] {aka GLFND, MIR1}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, TFAM (transcription factor A, mitochondrial) [NCBI Gene 7019] {aka MTDPS15, MTTF1, MTTFA, TCF6, TCF6L1, TCF6L2}, PRKAB1 (protein kinase AMP-activated non-catalytic subunit beta 1) [NCBI Gene 5564] {aka AMPK, HAMPKb}, MIR206 (microRNA 206) [NCBI Gene 406989] {aka MIRN206, miRNA206, mir-206}, IGKV5-2 (immunoglobulin kappa variable 5-2) [NCBI Gene 28907] {aka B2, IGKV52}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MIR486-1 (microRNA 486-1) [NCBI Gene 619554] {aka MIR486, MIRN486, hsa-mir-486, hsa-mir-486-1, mir-486-1}, TSC2 (TSC complex subunit 2) [NCBI Gene 7249] {aka LAM, PPP1R160, TSC4}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, STAT5A (signal transducer and activator of transcription 5A) [NCBI Gene 6776] {aka MGF, STAT5}, ULK1 (unc-51 like autophagy activating kinase 1) [NCBI Gene 8408] {aka ATG1, ATG1A, UNC51, Unc51.1, hATG1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, STK11 (serine/threonine kinase 11) [NCBI Gene 6794] {aka LKB1, PJS, hLKB1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}, DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786] {aka ADCADN, AIM, CXXC9, DNMT, HSN1E, MCMT}, ACACA (acetyl-CoA carboxylase alpha) [NCBI Gene 31] {aka ACAC, ACACAD, ACACalpha, ACC, ACC1, ACCA}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, EPO (erythropoietin) [NCBI Gene 2056] {aka DBAL, ECYT5, EP, MVCD2}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MIR378A (microRNA 378a) [NCBI Gene 494327] {aka MIR378, MIRN378, hsa-mir-378, hsa-mir-378a, miRNA378}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, FOXO3 (forkhead box O3) [NCBI Gene 2309] {aka AF6q21, FKHRL1, FKHRL1P2, FOXO2, FOXO3A}, SGK1 (serum/glucocorticoid regulated kinase 1) [NCBI Gene 6446] {aka SGK}, NUP62 (nucleoporin 62) [NCBI Gene 23636] {aka IBSN, SNDI, p62}, CAT (catalase) [NCBI Gene 847], RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 6198] {aka PS6K, S6K, S6K-beta-1, S6K1, STK14A, p70 S6KA}, MIR34A (microRNA 34a) [NCBI Gene 407040] {aka MIRN34A, miRNA34A, mir-34, mir-34a}, MIR494 (microRNA 494) [NCBI Gene 574452] {aka MIRN494, hsa-mir-494, mir-494}, PDK4 (pyruvate dehydrogenase kinase 4) [NCBI Gene 5166], CAMKK2 (calcium/calmodulin dependent protein kinase kinase 2) [NCBI Gene 10645] {aka CAMKK, CAMKKB}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, KAT2A (lysine acetyltransferase 2A) [NCBI Gene 2648] {aka GCN5, GCN5L2, PCAF-b, hGCN5}, NAMPT (nicotinamide phosphoribosyltransferase) [NCBI Gene 10135] {aka 1110035O14Rik, PBEF, PBEF1, VF, VISFATIN}
- **Diseases:** Hypoxia (MESH:D000860), hemolysis (MESH:D006461), renal neoplasms (MESH:D007680), Metabolic Overdrive (MESH:D008659), tumorigenesis (MESH:D063646), fatigue (MESH:D005221), Hypoxic-Erythropoietic (MESH:D002534), overnutrition (MESH:D044343), cancer (MESH:D009369), Mitochondrial dysfunction (MESH:D028361), inflammation (MESH:D007249), injury to (MESH:D014947), disease (MESH:D004194), metabolic and oncologic disorders (MESH:D000072716), rigidity (MESH:D009127), hepatocellular carcinoma (MESH:D006528), cardiac hypertrophy (MESH:D006332), hypertrophy (MESH:D006984), hepatic adenomas (MESH:C564190), tumorigenic (MESH:D002471)
- **Chemicals:** 8-oxo-2'-deoxyguanosine (MESH:D000080242), SAH (MESH:D012435), resveratrol (MESH:D000077185), S-adenosylmethionine (MESH:D012436), acetyl-CoA (MESH:D000105), nucleotide (MESH:D009711), metformin (MESH:D008687), leucine (MESH:D007930), 5-methylcytosine (MESH:D044503), cortisol (MESH:D006854), lactate (MESH:D019344), oxygen (MESH:D010100), acids (MESH:D000143), clenbuterol (MESH:D002976), EGCG (MESH:C045651), succinate (MESH:D019802), methionine (MESH:D008715), ROS (MESH:D017382), calcium (MESH:D002118), berberine (MESH:D001599), glucose (MESH:D005947), fumarate (MESH:D005650), TBARS (MESH:D017392), NAD+ (MESH:D009243), lipid (MESH:D008055), steroid (MESH:D013256), GSH (MESH:D005978), polyphenol (MESH:D059808), ATP (MESH:D000255), AMP (MESH:D000249), fatty-acid (MESH:D005227), carbohydrate (MESH:D002241), GSSG (MESH:D019803), Amino acids (MESH:D000596), AICAR (MESH:C031143), poly(ADP-ribose) (MESH:D011064), caffeine (MESH:D002110), alpha-KG (MESH:D007656), curcumin (MESH:D003474), AAS (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rodentia (rodent, order) [taxon 9989]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940591/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940591/full.md

## References

129 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940591/full.md

---
Source: https://tomesphere.com/paper/PMC12940591